A recent study found that the generic version of capecitabine has yielded less cost savings over a 3-year span than expected, which is likely a reflection of the lack of generic manufacturers entering the market. READ MORE
Scott Glaser, MD, presented results from a study evaluating chemotherapy and radiation therapy in the largest group of patients with stage 2 testicular seminoma ever recorded.
Shorter radiation courses followed by consolidation chemotherapy before surgery may be an effective treatment option for rectal cancer patients.
Roger Longman, MA, offers a perspective on how we can overcome comparative effectiveness research and bring a greater understanding on which drugs work best.
The debate continues to rage over the current cost of cancer care and the value that these drugs bring to patients.
Clinical Pathways in Community Oncology: Assessing the Work of the American Society of Clinical Oncology Task Force on Clinical Pathways
Journal of Clinical Pathways spoke with Robin Zon, MD, FACP, FASCO, chair of ASCO’s Task Force on Clinical Pathways and medical oncologist at Michiana Hematology Oncology, Mishawaka, IN.
A recent study found that the generic version of capecitabine has yielded less cost savings over a 3-year span than expected, which is likely a reflection of the lack of generic manufacturers entering the market.
A multikinase inhibitor used in the second-line setting for hepatocellular carcinoma offers limited increases in quality-adjusted life years.
A long-term post-hoc analysis compared the effects of three therapy regimens for the initial treatment of patients with a type of advanced-stage B-cell malignancy.
A recent report suggests that there is a steady increase in costs of FDA approved anticancer drugs over time, regardless of competition or supplemental indications.
Research in Review
More than 23% of patients with breast cancer who undergo breast-conserving surgery followed by subsequent surgery do not receive the full benefits of surgery due to added costs and complications.
Researchers identified which imaging technique is better for evaluating prognosis of newly-diagnosed multiple myeloma.
Intensified regimens improve event-free survival and overall survival in patients newly diagnosed with diffuse large B-cell lymphoma compared with standard therapy.
A recent analysis reports a cost-effective alternative modality that demonstrates similar efficacy to traditional breast MRI.